HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Deals

M&A, licensing, and major transactions shaping the industry

Lilly, Gilead lead pharma’s M&A boom
DealsBioPharma Dive ↗
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer a…
May 8, 2026
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
DealsFiercePharma ↗
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalys…
May 8, 2026
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
DealsFierceBiotech ↗
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
Roche is set to pay out a little more than $1 billion to acquire digital pathology specialist Path AI in a mov…
May 8, 2026
Lilly, Gilead lead pharma’s M&A boom
DealsPharmaVoice ↗
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.…
May 7, 2026
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
DealsFierceBiotech ↗
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s hea…
May 7, 2026
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
DealsBriefing
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
The $300M upfront deal gives Bayer control of PER-001, a midphase implant for glaucoma and diabetic retinopath…
May 7, 2026
← Newer Page 4 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.